Labcorp has maintained a clean four-quarter earnings beat streak and converts free cash flow well above net income, but the stock has triggered a hard technical block — trading below its long-term moving average — while facing heavy revenue concentration in one business segment and one geography, and an insufficient reward-to-risk ratio that supports only a hold-and-watch posture.
Thesis pillars
- Clean Four Quarter Beat Streak↑Improving
- Death Cross Technical Hard Block→Stable
- High Revenue Concentration Risk↑Improving
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Feb 24, 2026
Labcorp Holdings Inc. (LH) Stock Analysis
Healthcare · Diagnostics & Research
Hold if already holding. Not a fresh buy at $360.25, but acceptable to hold if already in. Reasons: Concentration risk — Product: Dx segment (78.0%); Concentration risk — Geographic: North America (87.0%).
Labcorp Holdings provides diagnostic laboratory testing and biopharma drug development services globally through Dx (routine and specialty testing) and BLS (clinical trial support) segments. The company generated $13,951.7 million in 2025 revenues with nearly 71,000 employees... Read more
Hold if already holding. Not a fresh buy at $360.25, but acceptable to hold if already in. Reasons: Concentration risk — Product: Dx segment (78.0%); Concentration risk — Geographic: North America (87.0%). Chart setup: No clear chart pattern; technical signals are mixed. Mixed signals. Hold existing position. Score 5.8/10, moderate confidence.
Passes 7/8 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
About Labcorp Holdings Inc.
About Labcorp Holdings Inc.
Labcorp Holdings generated $13,951.7 million in 2025 revenues through the Dx segment ($10,876.5 million, 78%) covering routine and specialty testing across more than 2,200 U.S. patient service centers, and the BLS segment ($3,098.2 million, 22%) supporting drug development globally. Nearly 71,000 employees served clients in about 100 countries, and BLS supported 85% of new FDA-approved drugs in 2025.
Dx earns fee-for-service revenue billed to four payer groups: MCOs and third parties (37% of total 2025 revenues), physician and hospital clients (23%), patients (10%), and Medicare/Medicaid (8%). MCO payments are predominantly fee-for-service with a smaller portion under per-member, per-month capitation arrangements. BLS earns fees from pharmaceutical and biotechnology companies for early development research, central laboratory services for clinical trials, and drug approval-related testing; about 59% of BLS revenues originate outside the U.S. The company also offers more than 100 health and wellness tests through its Labcorp OnDemand consumer channel. Since January 1, 2021, the company has invested approximately $3.8 billion in strategic acquisitions, including a 2025 minority stake in SYNLAB for European specialty diagnostics. Nearly all Dx revenue originates in the U.S., while BLS maintains a global central laboratory network with nine ISO 15189-certified locations.
Show full overview
Medicare reimbursement for clinical laboratory testing follows a government-set schedule under PAMA. Rate reductions imposed from 2018 to 2020 cut reimbursement by approximately $245.0 million. Under the Consolidated Appropriations Act signed February 3, 2026, rate changes are frozen for 2026 but phased reductions will resume from 2027 through 2029 capped at 15% per year, with benchmark rates set from CMS's 2025 data collection window. Given Dx accounts for 78% of Labcorp's revenues, PAMA-driven compression on core clinical test reimbursement subjects the majority of the company's revenue base to government-mandated price controls through 2029.
See also: Healthcare · Diagnostics & Research
From Labcorp Holdings Inc.'s most recent 10-K filing, extracted June 11, 2026.
Recent developments
updated 2026-10-29Recent Developments — Labcorp Holdings Inc.
Latest news
- NEWS Labcorp (LH) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates - Yahoo Finance — Yahoo Finance neutral
- NEWS Labcorp (LH) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates - finance.yahoo.com — finance.yahoo.com neutral
- NEWS What To Expect From Labcorp’s (LH) Q2 Earnings - TradingView — TradingView positive
- NEWS What To Expect From Labcorp’s (LH) Q2 Earnings - tradingview.com — tradingview.com neutral
- NEWS What To Expect From Labcorp’s (LH) Q1 Earnings - StockStory — StockStory neutral
Generated 2026-10-29T11:14:33Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductDx segment78%10-K Item 1: 'Total Dx revenues ... 78'
- MEDIUMCustomerThird party37%10-K Item 1: 'Third party ... 37'
- HIGHGeographicNorth America87%10-K Item 1: 'North America ... 87'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·1 ceiling hit
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $360.25, but acceptable to hold if already in. Reasons: Concentration risk — Product: Dx segment (78.0%); Concentration risk — Geographic: North America (87.0%). Chart setup: No clear chart pattern; technical signals are mixed. Mixed signals. Hold existing position. Analyst target $319.05 reached (−11.4%), stop $340.69 (−5.7%), A.R:R -0.8:1. Score 5.8/10, moderate confidence.
Analyst target $319.05 reached (−11.4% from $360.25); no take-profit level is published. Analyst target $319.05 reached (−11.4%), stop $340.69 (−5.7%), A.R:R -0.8:1. Stop-loss: $340.69.
Concentration risk — Product: Dx segment (78.0%); Concentration risk — Geographic: North America (87.0%); Analyst target reached - limited upside remaining.
Labcorp Holdings Inc. trades at a P/E of 29.5 (forward 18.3). TrendMatrix value score: 5.4/10. Verdict: Hold.
27 analysts cover LH with a consensus score of 4.1/5. Average price target: $355.
What does Labcorp Holdings Inc. do?Labcorp Holdings provides diagnostic laboratory testing and biopharma drug development services globally through Dx...
Labcorp Holdings provides diagnostic laboratory testing and biopharma drug development services globally through Dx (routine and specialty testing) and BLS (clinical trial support) segments. The company generated $13,951.7 million in 2025 revenues with nearly 71,000 employees serving clients in approximately 100 countries, with Dx accounting for 78% and BLS 22% of revenues.